Skip to main content
Publications
Lytras T, Beckmeyer-Borowko A, Kogevinas M, Kromhout H, Carsin AE, Anto JM, Bentouhami H, Weyler J, Heinrich J, Nowak D, Urrutia I, Martinez-Moratalla J, Gullon JA, Pereira Vega A, Raherison Semjen C, Pin I, Demoly P, Leynaert B, Villani S, Gislason T, Svanes O, Holm M, Forsberg B, Norback D, Mehta AJ, Keidel D, Vernez D, Benke G, Jogi D, Toren K, Sigsgaard T, Schlunssen V, Olivieri M, Blanc PD, Watkins J, Bono R, Squillacioti G, Buist AS, Vermeulen R, Jarvis D, Probst-Hensch N, Zock JP. Cumulative occupational exposures and lung-function decline in two large general-population cohorts. Ann Am Thorac Soc. 2021 Feb;18(2):238-46. doi: 10.1513/AnnalsATS.202002-113OC
Davenport MS, Montgomery JS, Kunju LP, Siddiqui J, Shanka PR, Rajendiran T, Shao X, Lee E, Barnett CL, Denton BT, Piert M. 18F-choline PET/mpMRI for detection of clinically significant prostate cancer: Part 1. Improved risk stratification for MRI-guided transrectal prostate biopsies. J Nucl Med. 2019 Aug 16. doi: 10.2967/jnumed.119.225789.
Ko DT, Khan AM, Kotrri G, Austin PC, Wijeysundera HC, Koh M, Chu A, Jackevicius CA, Lawler PR, Tu JV. Eligibility, clinical outcomes, and budget impact of PCSK9 inhibitor adoption: the CANHEART PCSK9 study. J Am Heart Assoc. 2018 Nov 6;7(21):e010007. doi: 10.1161/JAHA.118.010007